Skip to main content
OpenTrials
Completed

NCT Number: NCT03178695

Inovium Ovarian Rejuvenation Trials

The Inovium Ovarian Rejuvenation Treatment is a PRP-based autologous treatment used in combination with a stimulated IVF sequence and Pre-Implantation Genetic Screening to treat infertility in women experiencing menopause, perimenopause, and premature ovarian failure.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Perimenopausal Disorder Adnexal Diseases Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Gonadal Disorders Infertility Infertility Unexplained Infertility, Female Menopause Menopause Premature Asymptomatic Menopause Premature Symptomatic Menopause Related Conditions Menopause, Premature Ovarian Diseases Ovarian Dysgenesis 2 Premature Ovarian Failure Premature Ovarian Failure 1 Premature Ovarian Failure 2A Premature Ovarian Failure 3 Premature Ovarian Failure 4 Premature Ovarian Failure 5 Premature Ovarian Failure 6 Premature Ovarian Failure 7 Premature Ovarian Failure 8 Premature Ovarian Failure 9 Premature Ovarian Failure, Familial Primary Ovarian Insufficiency Urogenital Diseases

Age range

35 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1

Primary location

Center for Advanced Genetics

Carlsbad, California, 92008, United States

About this study

This research extends earlier work conducted by Inovium associates in Athens, Greece who demonstrated efficacy of intraovarian injection of autologous PRP for resumption of menses, hormone stabilization, and conception after IVF in multiple women following PRP+natural cycle IVF (i.e., without gonadotropin stimulation). The use of stimulation (gonadotropins) and targeted pre- and posttreatment hormone monitoring during this clinical trial aims to characterize more fully the transition from PRP dosing, embryogenesis, IVF and conception.

The current study seeks to describe how PRP works to rejuvenate immune system and ovarian stem cells, restore menses, provide hormone stability, and generate successful IVF sequences and conceptions. The quality of all embryos generated will be studied via PGS, with the goal of generating euploid embryos. Hormone stability and biomarkers of aging will also be evaluated to understand the extent of any observed benefits, and to estimate how long such effects may be sustained with a single PRP treatment.

Autologous activated PRP used in this clinical study is isolated from patient derived (blood) samples collected on-site, using FDA-approved Regenlab [Lausanne, Switzerland] BCT-1 PRP Kit and RegenLab Drucker Centrifuge (FDA 510(k)-Approval #BK110061; ISO#13485).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed and dated informed consent
  • Women over the age of 35
  • Primary or secondary amenorrhea at least for 3-6 months
  • Presence of at least one ovary
  • Agree to report any pregnancy to the research staff immediately.
  • Willing and able to comply with study requirements.
  • Willing to receive IVF to get pregnant as part of the experimental protocol.

Exclusion criteria

  • Men will be excluded from the study.
  • Current or previous IgA deficiency
  • Current or previous premature ovarian failure due to a genetic origin, such as Turner's Syndrome or chromosomal abnormality
  • Current or previous great injuries or adhesions to the pelvis or ovaries
  • Current and ongoing pregnancy
  • Current and ongoing anticoagulant use for which plasma infusion appears contraindicated
  • Current and ongoing major Mental health disorder that precludes participation in the study
  • Current and ongoing active substance abuse or dependence
  • Current and ongoing gynecological or non-gynecological cancer
  • Current and ongoing chronic pelvic pain

Treatment and study plan

Autologous PRP injection into human ovarian tissue

Other

Using FDA-approved equipment, blood plasma is received from participant, isolated/enriched into PRP, and infused into the ovaries under transvaginal ultrasound guidance.

Primary outcomes

  1. Positive IVF

    Time frame: 12 months

    Following the initial Ovarian Rejuvenation Treatment, subjects will undergo IVF treatment to test the efficacy of the Protocol for fertility outcomes, as per trial protocols.

  2. Positive Pregnancy and Conception

    Time frame: 12 months

    Following completion of trial protocols, patients will conduct ongoing post-treatment follow-up with trial staff for recording progress of all ongoing pregnancies and conceptions, via post-treatment correspondence.

Secondary outcomes

  1. Resumption of Menses

    Time frame: 12 months

    With Premature Ovarian Failure and natural menopause the normal menstrual cycle is disrupted and normal menses does not occur. Patients will monitor for resumption of menses.

  2. Changes in Hormone Levels

    Time frame: 12 months

    Changes in hormonal levels toward normal ranges. Hormones may include FSH/LH; Estradiol/ progesterone;Inhibin; Anti- Mullerian Hormone

  3. Changes in Egg Quality

    Time frame: 12 months

    Using Pre-Implantation Genetic Screening, the trials will study the changes to egg quality of all eggs generated as a result of the treatment. A comparison group of patients who have received standard IVF treatment without the Inovium Ovarian Rejuvenation Treatment will be used to study this outcome.

  4. Changes in Health Outcomes

    Time frame: 12 months

    Changes in overall health levels will be studied. A comparison group of patients who have received standard IVF treatment without the Inovium Ovarian Rejuvenation Treatment will be used to study this outcome. All patient data collected as described in the other outcomes will be used in this comparison.

  5. Duration of Identified Benefits of Treatment

    Time frame: 12 months

    The duration of effects will be studied, in order to identify a frequency of treatment necessary to sustain positive health and fertility outcomes.

  6. Changes in Menopausal Symptoms

    Time frame: 12 months

    A before-and-after questionnaire will be administered to collect patient personal experience data regarding changes in menopausal symptoms.

Sponsors and collaborators

Lead sponsor

Ascendance Biomedical

Industry

Registry information

Official study title

Autologous Platelet-Rich Plasma (PRP) Infusions and Biomarkers of Ovarian Rejuvenation and Aging Mitigation

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jun 7, 2017
Registry last updated
Apr 20, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.